Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Aprepitant on Bosutinib PK in Healthy Subjects
NCT02058277Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosutinib in chronic myeloid leukemia (CML), sponsored by Pfizer. Primary endpoints: Area under the Concentration-Time Curve at 96 hours and Maximum Observed Plasma Concentration at 96 hours. Started May 2014; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02058277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058277.